NexGel Reports Q2 2026 Results With Adjusted Net Loss
NexGel reported Q2 revenue of $3.69 million and a net loss of $2.87 million. The company is integrating the Celularity transaction, facing supply chain challenges in its BioNX Surgical division, and shifting focus to the hospital market for the SilverSeal product.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day